Last reviewed · How we verify
tetracaine 4% gel
At a glance
| Generic name | tetracaine 4% gel |
|---|---|
| Also known as | Ametop |
| Sponsor | Fraser Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Experience Using Lidocaine Adrenaline Tetracaine (LAT) Gel Versus Lidocaine Infiltration for Laceration Repair in Adults (PHASE4)
- Uddevalla Skövde Transscleral Micropulse Study
- Topical Amethocaine Gel for Intramuscular Injection in Term Neonates (PHASE2)
- Comparison of Two Application Techniques for LET Gel (PHASE4)
- Comparison of 2 Application Techniques for LET Gel Used Prior to Simple Laceration Repair (PHASE4)
- Prospective Evaluation of Topical Anesthesia in Children (NA)
- Ametop Compared to Ametop With Pain Ease Spray (NA)
- Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tetracaine 4% gel CI brief — competitive landscape report
- tetracaine 4% gel updates RSS · CI watch RSS
- Fraser Health portfolio CI